Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

Key Takeaways

• BOT + BAL showed 17% ORR in heavily pretreated HCC patients.
• Median overall survival reached 12.3 months, exceeding typical post‑ICI benchmarks.
• 47% of cohort had ALBI grade 2 liver function, indicating poor prognosis.
• Immune‑mediated adverse events occurred in 68%, with no grade 4+ events.
• Clinical benefit rate 50% at 18 weeks, with disease stable 66 weeks.

Pulse Analysis

The landscape of advanced hepatocellular carcinoma (HCC) has been reshaped by frontline checkpoint inhibitor combos, yet a sizable subset of patients inevitably progress after such regimens. Historically, second‑line options—lenvatinib, cabozantinib, regorafenib—have delivered modest response rates and overall survival rarely exceeding ten months, leaving a therapeutic gap for those with compromised liver function. In this context, Agenus' Phase 1b expansion cohort provides a rare prospective glimpse into outcomes for a post‑ICI population that includes nearly half of the patients with ALBI grade 2, a marker linked to poorer prognosis.

The trial’s efficacy signals are noteworthy. An objective response rate of 17%—including a complete response—paired with a 50% clinical benefit rate at 18 weeks suggests that the Fc‑enhanced CTLA‑4 antibody botensilimab can synergize with the PD‑1 blocker balstilimab to rekindle immune activity where conventional checkpoint approaches have stalled. Median overall survival of 12.3 months surpasses the ≤10.5‑month benchmark of existing second‑line agents, while a median progression‑free survival of 4.4 months aligns with, if not exceeds, historical data. Importantly, the durability of disease control is highlighted by a patient maintaining stable disease for 66 weeks, underscoring potential long‑term benefit beyond RECIST responses.

For Agenus, these findings reinforce the strategic value of its next‑generation immuno‑oncology platform. The manageable safety profile—immune‑mediated events in 68% of patients, none reaching grade 4—supports broader development across solid tumors with limited treatment options. As the company advances the global Phase 3 BATTMAN trial in colorectal cancer and seeks regulatory pathways for HCC, the Phase 1b data could accelerate market entry, attract partnership interest, and ultimately expand the pool of patients who benefit from checkpoint‑based combinations. The emerging evidence positions botensilimab + balstilimab as a compelling candidate to fill the post‑immunotherapy void in liver cancer.